Clinical Trial: Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional

Official Title: A Single Center Pilot Trial of Rituximab in the Treatment of Fibrillary Glomerulonephritis

Brief Summary: Will use of Rituximab reduce proteinuria over a 12 month period and will there be preservation of kidney function with the use of this study drug?

Detailed Summary:

This is a Phase II, open-label study to determine if the use of Rituximab reduces proteinuria over a 12 month period and is there preservation of kidney function with the use of this study drug.

Aim 1) Preservation of kidney function at 12 months as defined by stable or improved 24 hour creatinine clearance.

Aim 2) Reduction in proteinuria at 12 months & improved quality of life at 12 months validated by questionnaire.


Sponsor: Mayo Clinic

Current Primary Outcome: Preservation of kidney function [ Time Frame: 12 months ]

Preservation of kidney function with the use of rituximab at 12 months as defined by stable or improved 24 hour creatinine clearance.


Original Primary Outcome: Same as current

Current Secondary Outcome: Reduction in proteinuria [ Time Frame: 12 months ]

Reduction in proteinuria with the use of rituximab at 12 months & improved quality of life at 12 months validated by questionnaire.


Original Secondary Outcome: Same as current

Information By: Mayo Clinic

Dates:
Date Received: July 21, 2014
Date Started: November 2014
Date Completion: April 2017
Last Updated: April 27, 2016
Last Verified: April 2016